Attached files
file | filename |
---|---|
EX-99.1 - WaferGen Bio-systems, Inc. | v173379_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): February 4, 2010
WaferGen
Bio-systems, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
333-136424
|
20-3699764
|
||
(State
or other jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
||
of
incorporation)
|
File
Number)
|
Identification
No.)
|
||
Bayside
Technology Center
46531
Fremont Blvd.
Fremont,
CA
|
94538
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (510) 651-4450
Not
Applicable
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction
A.2. below):
*
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
*
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
*
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
*
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
7.01. Regulation FD Disclosure.
On February 4, 2010, WaferGen
Bio-systems, Inc. (the “Company”) issued a press release announcing that its
Chairman, President and CEO, Alnoor Shivji, will deliver a presentation at the
12th annual BIO CEO and Investor Conference in New York at The Waldorf-Astoria
Hotel on Monday, February 8, 2010, at 8:30 a.m. Eastern Time. Mr.
Shivji’s presentation will cover the company’s progress toward positioning the
WaferGen SmartChip™ Real-Time PCR System as the platform of choice for biomarker
discovery and validation. This presentation may be accessed by the
public via live webcast at www.wafergen.com. The webcast will be
archived until May 9, 2010. A copy of the press release issued by the
Company is attached hereto as Exhibit 99.1
The information in this Current Report
on Form 8−K, including Exhibit 99.1, shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934, as amended, except as we may
specifically state in any such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
|
Description
|
|
99.1
|
Press
release, issued February 4, 2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
WaferGen
Bio-systems, Inc.
|
||
Date:
February 5, 2010
|
By:
|
/s/
Alnoor Shivji
|
Alnoor
Shivji
|
||
Chairman,
President and Chief Executive
Officer
|
2